Moving towards individualized medicine with pharmacogenomics

Nature

Volumn 429, Issue 6990, 2004, Pages 464-468

  Evans, William E ^a,b,c   Relling, Mary V ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Pharmacogenet Anticancer A R G   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA SEQUENCES; DRUG PRODUCTS; DRUG THERAPY; GENES; MOLECULAR DYNAMICS; OPTIMIZATION; PROTEINS;

MULTIGENE DETERMINANTS; PHARMACOGENOMICS;

BIOMEDICAL ENGINEERING;

ABACAVIR; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARMUSTINE; CISAPRIDE; CLARITHROMYCIN; CODEINE; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; ERYTHROMYCIN; FLUOROURACIL; IRINOTECAN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVODOPA; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PRAVASTATIN; QUINIDINE; SIMVASTATIN; TACROLIMUS; TERFENADINE; TIOGUANINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

MEDICINE;

DIAGNOSTIC PROCEDURE; DNA SEQUENCE; DRUG TARGETING; GENE EXPRESSION; GENETIC LINKAGE; GENETIC TRAIT; GENOMICS; HUMAN; PENETRANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOMICS; HUMANS; MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 2642570170     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02626     Document Type: Review

References (30)

1. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
2. Vesell, E. S. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther. 41, 535-552 (1989).
3. Guengerich F. P. et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab. Dispos. 26, 1175-1178 (1998).
4. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
5. Gonzalez, F. J. et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446 (1988).
6. Evans, W. E. & Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
7. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
8. Evans, W. E. & McLeod, H. L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
9. Evans W. E. et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol. 19, 2293-2301 (2001).
10. Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D. & Roberts, W. M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyl transferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119, 985-989 (1991).
11. Marshall, E. Preventing toxicity with a gene test. Science 302, 588-590 (2003).
12. Abbott, A. With your genes? Take one of these, three times a day. Nature 425, 760-762 (2003).
13. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a Systematic review. J. Am. Med. Assoc. 286, 2270-2279 (2001).
14. Eichelbaum, M., Spannbrucker, N. & Dengler, H. J. N-oxidation of sparteine in man and its interindividual differences. Naunyn Schmiedebergs Arch. Pharmacol. 287, R94 (1975).
15. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. & Smith, R. L. Polymorphic hydroxylatinn of Debrisoquine in man. Lancet 2, 584-586 (1977).
16. Ingelman-Sundberg, M., Oscarson, M. & McLellan, R. A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342-349 (1999).
17. Cheok, M. H. et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet. 34, 85-90 (2003).
18. Buetow, K. H. et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Natl Acad. Sci. USA 98, 581-584 (2001).
19. Liotta, L. A., Kohn, E. C. & Petricoin, E. F. Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286, 2211-2214 (2001).
20. Golub, T. R. Mining the genome for combination therapies. Nature Med. 9, 510-511 (2003).
21. Stegmaier, K. et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004).
22. Evans, W. E. & Guy, R. K. Gene expression as a drug discovery tool. Nature Genet. 36, 214-215 (2004).
23. Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
24. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27, 393-391 (2001).
25. Holden, C. Race and medicine. Science 302, 594-596 (2003).
26. Rosenberg, N. A. et al. Genetic structure of human populations. Science 299, 2391-2395 (2002).
27. Burchard, E. G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J Med. 348, 1170-1175 (2003).
28. Eccles, D. M. Genetic testing for BRCA1 mutation in the UK. Lancet 361, 178-179 (2003).
29. Altman, R. B. et al. Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13, 3-5 (2003).
30. Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. Pharmacogenetics goes genomic. Nature Rev. Genet. 4, 937-947 (2003).